Want to see IN:JAGSNPHARM full AI Analyst Report?
JAGSNPHARM Stock Chart & Stats
₹193.50
-₹13.50(-5.18%)
At close: 4:00 PM EST
₹193.50
-₹13.50(-5.18%)
Day’s Range― - ―
52-Week Range₹154.90 - ₹301.80
Previous CloseN/A
Volume94.85K
Average Volume (3M)3.85K
Market Cap
₹15.36B
Enterprise Value₹14.03B
Total Cash (Recent Filing)₹1.06B
Total Debt (Recent Filing)₹81.65M
Price to Earnings (P/E)36.4
Beta1.02
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)6.40
Shares Outstanding65,835,470
10 Day Avg. Volume3,534
30 Day Avg. Volume3,854
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives the company durable financial flexibility to fund working capital, invest in field force or product launches, and absorb sector shocks without relying on external debt. This supports long-term strategic options and capital allocation discipline.
Strong Cash GenerationConsistent operating cash conversion above net income and near parity of free cash flow to earnings indicates high earnings quality and internal funding capacity. This durability supports reinvestment, working capital needs and shareholder returns without heavy financing.
Re-accelerated Revenue Growth With Healthy MarginsA sharp re-acceleration in revenue coupled with sustainably high gross and operating margins points to favorable product mix, pricing power and execution. These structural traits support cash flow resilience and the ability to scale profitably over the medium term.
Bears Say
Profitability VolatilityDeclines in net income despite higher revenue and multi-year margin swings reduce predictability of earnings and returns. For a prescription-branded business, volatility complicates investment planning, forecasting and may signal pricing, cost or mix risks that persist.
Choppy Cash Conversion HistoryWhile recent cash conversion is strong, prior inconsistent conversion driven by working-capital swings implies cash flows can be timing-sensitive. Structural swings in receivables/inventory can strain liquidity in downturns and complicate sustained capital deployment.
Negative EPS GrowthA substantial negative EPS growth rate indicates that earnings per share have contracted recently, reducing sustainable return on equity and signaling possible margin pressures or one-off items. This undermines long-term earnings momentum and financial predictability.
Jagsonpal Pharmaceuticals Ltd. News
JAGSNPHARM FAQ
What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?
Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.
What is Jagsonpal Pharmaceuticals Ltd.’s market cap?
Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹15.36B.
When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?
Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 24 days.
How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?
Jagsonpal Pharmaceuticals Ltd. released its earnings results on Apr 27, 2026. The company reported ₹1.25 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.25.
Is Jagsonpal Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Jagsonpal Pharmaceuticals Ltd. pay dividends?
Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here
What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?
Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?
Jagsonpal Pharmaceuticals Ltd. has 65,835,470 shares outstanding.
What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?
Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.256%.
Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JAGSNPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spans three primary therapeutic domains: women's health, pain management and analgesia, and general medical care. Within general medicine, the company offers solutions for allergy control, immune and cellular protection, gastrointestinal and mental wellness, anti-infectives, and products specifically for dental and ear, nose, and throat (ENT) conditions. For women's healthcare, their offerings include pregnancy support and treatments for issues related to dysfunctional uterine bleeding. Furthermore, Jagsonpal provides medications for pain relief and skeletal and joint health. These pharmaceutical items are supplied in common forms like tablets, capsules, and syrups. The company operates as a subsidiary under Aresko Progressive Private Limited.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Sakar Healthcare Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―